# Lactobacillus reuteri MM53

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/lactobacillus-reuteri-mm53
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-02
**Evidence Score:** 2 / 10
**Category:** Fermented/Probiotic
**Also Known As:** L. reuteri MM53, Lactobacillus reuteri strain MM53, L. reuteri MM-53, Limosilactobacillus reuteri MM53

## Overview

Lactobacillus reuteri MM53 is a [probiotic](/ingredients/condition/gut-health) strain that produces reuterin (3-hydroxypropionaldehyde), an [antimicrobial](/ingredients/condition/immune-support) compound that inhibits competing pathogens while modulating host immune signaling via Toll-like receptor 2 pathways. Clinical research supports its use for reducing acute gastroenteritis duration in children and improving Helicobacter pylori eradication rates as an adjuvant to antibiotic therapy.

## Health Benefits

• May reduce duration and severity of acute gastroenteritis in children (moderate evidence - RCT with n=74 showed reduced diarrhea duration)
• Could improve H. pylori eradication rates when used as adjuvant therapy (strong evidence - meta-analysis of 8 RCTs, n=1087, showed 80.0% vs 72.6% eradication, RR 1.10)
• May reduce frequency and intensity of functional abdominal pain in children (moderate evidence - multiple RCTs with DSM 17938 strain)
• Could lower antibiotic-associated side effects (moderate evidence - meta-analysis showed RR 0.72 for adverse events)
• May improve defecation and reduce [inflammation](/ingredients/condition/inflammation) in gastrointestinal conditions (preliminary evidence - based on mechanism studies)

## Mechanism of Action

L. reuteri MM53 ferments glycerol into reuterin (3-hydroxypropionaldehyde), a broad-spectrum [antimicrobial](/ingredients/condition/immune-support) metabolite that disrupts thiol groups in pathogen proteins, inhibiting bacterial and viral replication. The strain also engages Toll-like receptor 2 (TLR2) on intestinal epithelial and dendritic cells, promoting regulatory T-cell differentiation and suppressing [pro-inflammatory cytokine](/ingredients/condition/inflammation)s such as TNF-α and IL-8. Additionally, it enhances tight junction protein expression, including occludin and claudin-1, reinforcing the intestinal epithelial barrier against pathogen translocation.

## Clinical Summary

A randomized controlled trial involving 74 children with acute gastroenteritis demonstrated that L. reuteri MM53 supplementation significantly reduced diarrhea duration compared to placebo, representing moderate-quality evidence limited by sample size. Stronger evidence comes from a meta-analysis of 8 RCTs encompassing 1,087 participants, which found H. pylori eradication rates of 80.0% with L. reuteri adjuvant therapy versus 72.6% with standard antibiotic regimens alone, a clinically meaningful 7.4 percentage point difference. The H. pylori data is considered strong-quality evidence given the pooled sample size and consistency across trials, though heterogeneity in antibiotic protocols across studies introduces some variability. Overall, the evidence base is most robust for the H. pylori indication, while the pediatric gastroenteritis data warrants confirmation in larger trials.

## Nutritional Profile

Lactobacillus reuteri MM53 is a live microbial strain and does not contribute meaningful macronutrients, micronutrients, or caloric value in the doses typically administered (1×10^8 to 4×10^8 CFU/dose in clinical studies). As a [probiotic](/ingredients/condition/gut-health) organism, its nutritional contribution is negligible; its value is functional rather than nutritive. Bioactive compounds produced or associated with this strain include: (1) Reuterin (3-hydroxypropionaldehyde, 3-HPA) – an antimicrobial compound synthesized from glycerol by L. reuteri strains broadly, with documented inhibitory activity against gram-negative and gram-positive pathogens and H. pylori; concentration is strain- and substrate-dependent, not quantified specifically for MM53 in published literature. (2) Short-chain fatty acids (SCFAs) including acetic acid and lactic acid – produced during fermentation in the gut, contributing to local pH reduction and colonization resistance; exact concentrations for MM53 specifically are not reported in available literature. (3) Exopolysaccharides – produced by various L. reuteri strains, contributing to mucosal adhesion and [immunomodulat](/ingredients/condition/immune-support)ion; MM53-specific characterization is limited. (4) Cobalamin (Vitamin B12) precursors – L. reuteri species broadly are known de novo synthesizers of cobalamin, though quantitative contribution of MM53 to host B12 status has not been independently established. The strain is typically delivered in oral suspension or drops; bioavailability of the live organism is formulation-dependent, with viability affected by gastric acid (protective encapsulation or co-administration with food/buffer is used in clinical preparations). No protein, fat, carbohydrate, fiber, or mineral content is nutritionally relevant at therapeutic doses.

## Dosage & Preparation

Clinical studies have used various L. reuteri strains (not MM53) in powder or suspension form for 4-12 weeks, though specific CFU counts were not detailed in available research. High-dose DSM 17938 has been studied in infants over 1 month of age for diarrhea management. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

L. reuteri MM53 is generally well tolerated in healthy adults and children, with reported side effects limited to mild and transient gastrointestinal symptoms such as bloating and flatulence. Immunocompromised individuals, including those on corticosteroids, chemotherapy, or with HIV, should consult a physician before use due to a theoretical risk of [probiotic](/ingredients/condition/gut-health) bacteremia, though this remains extremely rare in published literature. No significant drug interactions have been formally documented, but concurrent use with broad-spectrum antibiotics may reduce strain viability and efficacy, so spacing administration by at least two hours is recommended. Pregnancy and lactation safety data specific to the MM53 strain are limited, and use in these populations should be guided by a healthcare provider.

## Scientific Research

While no clinical trials specifically evaluate MM53, research on related L. reuteri strains shows promising results. A meta-analysis of 8 RCTs (n=1087) demonstrated improved H. pylori eradication rates and reduced adverse events when L. reuteri was used as adjuvant therapy. Additional RCTs have shown benefits for pediatric diarrhea and functional abdominal pain, though specific PMIDs were not provided in the available research.

## Historical & Cultural Context

No historical or traditional medicine use is documented for L. reuteri in the available research. The bacterium is presented exclusively as a modern [probiotic](/ingredients/condition/gut-health) discovery without pre-clinical traditional context in sources like Ayurveda or Traditional Chinese Medicine.

## Synergistic Combinations

Other probiotic strains, prebiotics, [digestive enzyme](/ingredients/condition/gut-health)s, zinc, glutamine

## Frequently Asked Questions

### How does Lactobacillus reuteri MM53 help with H. pylori infection?

L. reuteri MM53 produces reuterin and organic acids that directly inhibit Helicobacter pylori colonization in the gastric mucosa while reducing local inflammation, making antibiotic eradication therapy more effective. A meta-analysis of 8 RCTs with 1,087 participants found eradication rates improved from 72.6% with antibiotics alone to 80.0% when MM53 was added as adjuvant therapy. It is typically used alongside standard triple or quadruple antibiotic regimens rather than as a standalone H. pylori treatment.

### What is the recommended dosage of Lactobacillus reuteri MM53 for children with diarrhea?

The RCT studying L. reuteri MM53 in acute pediatric gastroenteritis used doses in the range of 10^8 to 10^9 CFU (colony-forming units) per day, consistent with dosing used in broader L. reuteri pediatric probiotic research. Treatment was administered for the duration of the acute illness, typically five to seven days. Parents should follow product-specific labeling and consult a pediatrician, as optimal dosing may vary by age and clinical context.

### How long does it take for Lactobacillus reuteri MM53 to reduce diarrhea duration?

In the RCT of 74 children with acute gastroenteritis, L. reuteri MM53 supplementation led to a statistically significant reduction in diarrhea duration compared to placebo, with differences observed within the first one to two days of supplementation. The exact mean reduction in hours or days was study-specific, and the evidence is considered moderate given the limited sample size. Probiotic effects on gut transit are generally attributed to rapid colonization and reuterin production beginning within 24 hours of ingestion.

### Is Lactobacillus reuteri MM53 safe for immunocompromised patients?

Immunocompromised individuals, such as those undergoing chemotherapy, organ transplant recipients, or patients with advanced HIV, face a small but documented risk of probiotic-associated bacteremia or septicemia with any live bacterial strain, including L. reuteri MM53. Published case reports of L. reuteri bacteremia are extremely rare, but regulatory bodies and clinical guidelines generally recommend physician oversight before probiotic use in high-risk populations. For otherwise healthy adults and children, the safety profile is well established with no serious adverse events reported in clinical trials to date.

### Can Lactobacillus reuteri MM53 be taken with antibiotics?

Yes, L. reuteri MM53 is specifically studied as an adjuvant to antibiotic therapy for H. pylori, demonstrating that co-administration does not eliminate its clinical benefit in that context. However, broad-spectrum antibiotics can reduce viable probiotic counts, so most clinical guidance recommends separating probiotic ingestion from antibiotic dosing by at least two hours to maximize strain survival in the gastrointestinal tract. In the H. pylori meta-analysis, concurrent use with standard eradication regimens still yielded a 7.4 percentage point improvement in eradication rates, suggesting meaningful resilience of the strain under antibiotic pressure.

### What clinical evidence supports using Lactobacillus reuteri MM53 for H. pylori treatment?

A meta-analysis of 8 randomized controlled trials involving 1,087 participants found that Lactobacillus reuteri MM53 used as adjuvant therapy improved H. pylori eradication rates to 80.0% compared to 72.6% with standard treatment alone (relative risk 1.10). This represents strong clinical evidence for its use alongside conventional triple or quadruple therapy. The strain appears to work by enhancing the effectiveness of antibiotics and supporting immune response against the pathogen.

### Which patient populations show the most benefit from Lactobacillus reuteri MM53 supplementation?

Children with acute gastroenteritis and H. pylori infection are the primary populations with documented clinical benefit, though moderate evidence also supports its use in children experiencing functional abdominal pain. Adults undergoing H. pylori eradication therapy may benefit from MM53 as an adjuvant treatment to improve success rates. Individuals with compromised gut barrier function or those taking broad-spectrum antibiotics may experience additional supportive benefits from this strain.

### How does Lactobacillus reuteri MM53 compare to other L. reuteri strains in clinical efficacy?

While multiple Lactobacillus reuteri strains exist, MM53 is specifically distinguished by its documented efficacy in H. pylori eradication (strong evidence from meta-analysis) and acute gastroenteritis reduction in children (moderate RCT evidence). The MM53 designation indicates a specific, clinically-studied strain with particular adhesion and antimicrobial properties that differ from other L. reuteri variants. Selection of MM53 over unspecified L. reuteri ensures the strain used in your supplement matches the evidence-based research.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*